Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors

Cancer Treatment Reviews

Volumn 39, Issue 1, 2013, Pages 27-43

  Kirkwood, John M ^a   Tarhini, Ahmad ^a   Sparano, Joseph A ^b   Patel, Prapti ^c   Schiller, Joan H ^c   Vergo, Maxwell T ^d   Benson III, Al B ^d   Tawbi, Hussein ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Adjuvant; Chemotherapy; Disease free survival; Immunotherapy; Molecularly targeted therapy; Neoplasms; Progression free survival

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEGINTERFERON ALPHA2B; TAMOXIFEN; TAXANE DERIVATIVE; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

ADJUVANT CHEMOTHERAPY; ALOPECIA; ANOREXIA; ARTHRALGIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CHILL; CLINICAL TRIAL (TOPIC); COLD SENSITIVITY; COLON CANCER; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG WITHDRAWAL; DYSESTHESIA; ENDOMETRIAL DISEASE; EVENT FREE SURVIVAL; EWING SARCOMA; EYE PAIN; FASCICULATION; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FLU LIKE SYNDROME; FRACTURE; HAND FOOT SYNDROME; HEADACHE; HOT FLUSH; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; JAW DISEASE; JAW TIGHTNESS; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE SPASM; MYALGIA; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; NIGHT SWEAT; OSTEOSARCOMA; OVERALL SURVIVAL; PARESTHESIA; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SARCOMA; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; SURVIVAL RATE; THROAT DISEASE; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT RESPONSE; VAGINA BLEEDING; VOICE CHANGE; VOMITING;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; HUMANS; IMMUNOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84869085064     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.03.007     Document Type: Review

References (194)

1. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology: Non-small Cell Lung Cancer V.1.2012 Available from: http://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf.
2. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
3. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer V.1.2012. Available from: http://www.nccn.org/professionals/physician_gls/PDF/colon.pdf.
4. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology: Bone Cancer V.2.2011. Available from: http://www.nccn.org/professionals/physician_gls/PDF/bone.pdf.
5. Bacci G., Ferrari S., Bertoni F., Rimondini S., Longhi A., Bacchini P., et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000, 18:4-11.
6. Fizazi K., Dohollou N., Blay J.Y., Guérin S., Le Cesne A., André F., et al. Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol 1998, 16:3736-3743.
7. Grier H.E., Krailo M.D., Tarbell N.J., Link M.P., Fryer C.J., Pritchard D.J., et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003, 348:694-701.
8. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma V.2.2011. Available from: http://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf.
9. Clemente C.G., Mihm M.C., Bufalino R., Zurrida S., Collini P., Cascinelli N. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996, 77:1303-1310.
10. Håkansson A., Gustafsson B., Krysander L., Håkansson L. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer 1996, 74:670-676.
11. Mihm M.C., Clemente C.G., Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996, 74:43-47.
12. Moschos S.J., Edington H.D., Land S.R., Rao U.N., Jukic D., Shipe-Spotloe J., et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 2006, 24:3164-3171.
13. + patients with renal cell carcinoma or melanoma. J Exp Med 2002, 196:619-628.
14. + T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. Cancer Res 2003, 63:4481-4489.
15. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer V.2.2011. Available from: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.
16. Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-5312.
17. Hayes D.F., Bast R.C., Desch C.E., Fritsche H., Kemeny N.E., Jessup J.M., et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996, 88:1456-1466.
18. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007, 131:18-43.
19. Carlson R.W., Brown E., Burstein H.J., Gradishar W.J., Hudis C.A., Loprinzi C., et al. NCCN Task Force Report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006, 4(Suppl. 1):S1-S26.
20. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995, 311:899-909.
21. Scagliotti G.V., Fossati R., Torri V., Crinò L., Giaccone G., Silvano G., et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell lung cancer. J Natl Cancer Inst 2003, 95:1453-1461.
22. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-360.
23. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005, 352:2589-2597.
24. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzáles-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006, 7:719-727.
25. Arriagada R., Dunant A., Pignon J.P., Bergman B., Chabowski M., Grunenwald D., et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010, 28:35-42.
26. Butts C.A., Ding K., Seymour L., Twumasi-Ankrah P., Graham B., Gandara D., et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010, 28:29-34.
27. Strauss G.M., Herndon J.E., Maddaus M.A., Johnstone D.W., Johnson E.A., Harpole D.H., et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008, 26:5043-5051.
28. Jang R.W., Le Maitre A., Ding K., Winton T., Bezjak A., Seymour L., et al. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J Clin Oncol 2009, 27:4268-4273.
29. Ng R., Hasan B., Mittmann N., Florescu M., Shepherd F.A., Ding K., et al. Economic analysis of NCIC CTG JBR.10: a randomized trial of adjuvant vinorelbine plus cisplatin compared with observation in early stage non-small-cell lung cancer - a report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:2256-2261.
30. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995, 345:939-944.
31. André T., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109-3116.
32. Yothers G., O'Connell M.J., Allegra C.J., Kuebler J.P., Colangelo L.H., Petrelli N.J., et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011, 29:3768-3774.
33. Quasar Collaborative Group, Gray R., Barnwell J., McConkey C., Hills R.K., Williams N.S., et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007, 370:2020-2029.
34. Twelves C., Wong A., Nowacki M.P., Abt M., Burris H., Carrato A., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352:2696-2704.
35. Haller D.G., Tabernero J., Maroun J., de Braud F., Price T., Van Cutsem E., et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011, 29:1465-1471.
36. Ychou M., Raoul J.L., Douillard J.Y., Gourgou-Bourgade S., Bugat R., Mineur L., et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol 2009, 20:674-680.
37. Saltz L.B., Niedzwiecki D., Hollis D., Goldberg R.M., Hantel A., Thomas J.P., et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007, 25:3456-3461.
38. Van Cutsem E., Labianca R., Bodoky G., Barone C., Aranda E., Nordlinger B., et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009, 27:3117-3125.
39. Allegra C.J., Yothers G., O'Connell M.J., Sharif S., Petrelli N.J., Colangelo L.H., et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011, 29:11-16.
40. De Gramont A., Van Cutsem E., Tabernero J., Moore M.J., Cunningham D., Rivera F., et al. AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. J Clin Oncol 2011, 29(Suppl. 4). [abstr 362].
41. Alberts S.R., Sargent D.J., Smyrk T.C., Shields A.F., Chan E., Goldberg R.M., et al. Adjuvant mFOLFOX6 with or without cetuxiumab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stage III colon cancer (CC): results from NCCTG intergroup phase III trial N0147. J Clin Oncol (Meeting Abstracts) 2010, 28:CRA3507.
42. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Goodman P.J., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990, 322:352-358.
43. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Tangen C.M., et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995, 122:321-326.
44. André T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
45. Kuebler J.P., Wieand H.S., O'Connell M.J., Smith R.E., Colangelo L.H., Yothers G., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25:2198-2204.
46. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., Laurie J.A., Tangen C.M., et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. J Clin Oncol 1995, 13:2936-2943.
47. Schippinger W., Samonigg H., Schaberl-Moser R., Greil R., Thödtmann R., Tschmelitsch J., et al. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 2007, 97:1021-1027.
48. Figueredo A., Charette M.L., Maroun J., Brouwers M.C., Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004, 22:3395-3407.
49. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999, 17:1356-1363.
50. O'Connor E.S., Greenblatt D.Y., LoConte N.K., Gangnon R.E., Liou J.I., Heise C.P., et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011, 29:3381-3388.
51. Grothey A., Nikcevich D.A., Sloan J.A., Kugler J.W., Silberstein P.T., Dentchev T., et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2011, 29:421-427.
52. Choti M.A. Chemotherapy-associated hepatotoxicity: do we need to be concerned?. Ann Surg Oncol 2009, 16:2391-2394.
53. Jackson McCleary N.A., Meyerhardt J., Green E., Yothers G., de Gramont A., Van Cutsem E., et al. Impact of older age on the efficacy of newer adjuvant therapies in >12,500 patients (pts) with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2009, 27. [abstr 4010].
54. Hsiao FS, Mullins CD, Onukwugha E, Pandya NB, Seal BS, Hanna N. Relative survival of adjuvant chemotherapy using 5-FU/LV alone, oxaliplatin, or irinotecan-based combination regimens among stage III colon cancer patients age 65 and older: an analysis using SEER-Medicare data. In: ASCO 2010 Gastrointestinal Cancers Symposium, Orlando, FL: January 22-24 2010 [abstr 360].
55. Argyriou A.A., Polychronopoulos P., Iconomou G., Chroni E., Kalofonos H.P. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat Rev 2008, 34:368-377.
56. Extra J.M., Espie M., Calvo F., Ferme C., Mignot L., Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990, 25:299-303.
57. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938-2947.
58. Wilson R.H., Lehky T., Thomas R.R., Quinn M.G., Floeter M.K., Grem J.L. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002, 20:1767-1774.
59. Quasthoff S., Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol 2002, 249:9-17.
60. Park S.B., Goldstein D., Lin C.S., Krishnan A.V., Friedlander M.L., Kiernan M.C. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 2009, 27:1243-1249.
61. Leonard G.D., Wright M.A., Quinn M.G., Fioravanti S., Harold N., Schuler B., et al. Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 2005, 5:116.
62. Lehky T.J., Leonard G.D., Wilson R.H., Grem J.L., Floeter M.K. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29:387-392.
63. Raymond E., Faivre S., Woynarowski J.M., Chaney S.G. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998, 25:4-12.
64. Aballea S., Chancellor J.V., Raikou M., Drummond M.F., Weinstein M.C., Jourdan S., et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 2007, 109:1082-1089.
65. Cortes E.P., Holland J.F., Wang J.J., Sinks L.F., Blom J., Senn H., et al. Amputation and adriamycin in primary osteosarcoma. N Engl J Med 1974, 291:998-1000.
66. Jaffe N., Frei E., Traggis D., Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med 1974, 291:994-997.
67. Rosen G., Marcove R.C., Huvos A.G., Caparros B.I., Lane J.M., Nirenberg A., et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. J Cancer Res Clin Oncol 1983, 106(Suppl.):55-67.
68. Sutow W.W., Sullivan M.P., Fernbach D.J., Cangir A., George S.L. Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study. Cancer 1975, 36:1598-1602.
69. Eilber F., Giuliano A., Eckardt J., Patterson K., Moseley S., Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987, 5:21-26.
70. Link M.P., Goorin A.M., Miser A.W., Green A.A., Pratt C.B., Belasco J.B., et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986, 314:1600-1606.
71. Meyers P.A., Heller G., Healey J., Huvos A., Lane J., Marcove R., et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992, 10:5-15.
72. Souhami R.L., Craft A.W., Van der Eijken J.W., Nooij M., Spooner D., Bramwell V.H., et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997, 350:911-917.
73. Antman K., Crowley J., Balcerzak S.P., Kempf R.A., Weiss R.B., Clamon G.H., et al. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. Cancer 1998, 82:1288-1295.
74. Winkler K., Beron G., Delling G., Heise U., Kabisch H., Purfürst C., et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988, 6:329-337.
75. Winkler K., Beron G., Kotz R., Salzer-Kuntschik M., Beck J., Beck W., et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol 1984, 2:617-624.
76. Gentet J.C., Brunat-Mentigny M., Demaille M.C., Pein F., Avet-Loiseau H., Berger C., et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. Eur J Cancer 1997, 33:232-237.
77. Goorin A.M., Harris M.B., Bernstein M., Ferguson W., Devidas M., Siegal G.P., et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 2002, 20:426-433.
78. Bacci G., Ferrari S., Comandone A., Zanone A., Ruggieri P., Longhi A., et al. Neoadjuvant chemotherapy for Ewing's sarcoma of bone in patients older than thirty-nine years. Acta Oncol 2000, 39:111-116.
79. Nesbit M.E., Gehan E.A., Burgert E.O., Vietti T.J., Cangir A., Tefft M., et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990, 8:1664-1674.
80. Burgert E.O., Nesbit M.E., Garnsey L.A., Gehan E.A., Herrmann J., Vietti T.J., et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990, 8:1514-1524.
81. Indelicato D.J., Keole S.R., Shahlaee A.H., Shi W., Morris C.G., Marcus R.B. Definitive radiotherapy for ewing tumors of extremities and pelvis: long-term disease control, limb function, and treatment toxicity. Int J Radiat Oncol Biol Phys 2008, 72:871-877.
82. Coindre J.M., Terrier P., Bui N.B., Bonichon F., Collin F., Le Doussal V., et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996, 14:869-877.
83. Pisters P.W., Leung D.H., Woodruff J., Shi W., Brennan M.F. Analysis of prognostic factors in 1041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996, 14:1679-1689.
84. Stefanovski P.D., Bidoli E., De Paoli A., Buonadonna A., Boz G., Libra M., et al. Prognostic factors in soft tissue sarcomas: a study of 395 patients. Eur J Surg Oncol 2002, 28:153-164.
85. Weitz J., Antonescu C.R., Brennan M.F. Localized extremity soft tissue sarcoma: improved knowledge with unchanged survival over time. J Clin Oncol 2003, 21:2719-2725.
86. Benjamin R.S., Wiernik P.H., Bachur N.R. Adriamycin: a new effective agent in the therapy of disseminated sarcomas. Med Pediatr Oncol 1975, 1:63-76.
87. O'Bryan R.M., Luce J.K., Talley R.W., Gottlieb J.A., Baker L.H., Bonadonna G. Phase II evaluation of adriamycin in human neoplasia. Cancer 1973, 32:1-8.
88. Edmonson J.H., Ryan L.M., Blum R.H., Brooks J.S., Shiraki M., Frytak S., et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993, 11:1269-1275.
89. Rosenberg S.A., Tepper J., Glatstein E., Costa J., Young R., Baker A., et al. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft tissue sarcomas of the extremities. Cancer 1983, 52:424-434.
90. Gherlinzoni F., Bacci G., Picci P., Capanna R., Calderoni P., Lorenzi E.G., et al. A randomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: preliminary observations. J Clin Oncol 1986, 4:552-558.
91. Ravaud A., Bui B.N., Coindre J., Kantor G., Stöckle E., Lagarde P., et al. Adjuvant chemotherapy with CYVADIC in high risk soft tissue sarcoma. A randomized prospective trial. Adjuvant therapy of cancer VI 1990, 556-566. WB Saunders, Philadelphia, PA. S.E. Salmon (Ed.).
92. Antman K., Suit H., Amato D., Corson J., Wood W., Proppe K., et al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups. J Clin Oncol 1984, 2:601-608.
93. Tierney J.F., Mosseri V., Stewart L.A., Souhami R.L., Parmar M.K. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer 1995, 72:469-475.
94. Zalupski M.M., Ryan J.R., Hussein M.E., Baker L.H. Defining the role of adjuvant chemotherapy for patients with soft tissue sarcoma of the extremities. Adjuvant therapy of cancer VII 1993, 385-392. JB Lippincott, Philadelphia. S.E. Salmon (Ed.).
95. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 1997, 350:1647-1654. Sarcoma Meta-analysis Collaboration.
96. Pervaiz N., Colterjohn N., Farrokhyar F., Tozer R., Figueredo A., Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008, 113:573-581.
97. Ginsberg J.P., Goodman P., Leisenring W., Ness K.K., Meyers P.A., Wolden S.L., et al. Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst 2010, 102:1272-1283.
98. Kuttesch J.F., Wexler L.H., Marcus R.B., Fairclough D., Weaver-McClure L., White M., et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 1996, 14:2818-2825.
99. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R., et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27:6199-6206.
100. Balch C.M., Buzaid A.C., Soong S.J., Atkins M.B., Cascinelli N., Coit D.G., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19:3635-3648.
101. Kirkwood J.M., Ibrahim J.G., Sondak V.K., Richards J., Flaherty L.E., Ernstoff M.S., et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000, 18:2444-2458.
102. Kirkwood J.M., Ibrahim J.G., Sosman J.A., Sondak V.K., Agarwala S.S., Ernstoff M.S., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001, 19:2370-2380.
103. Kirkwood J.M., Manola J., Ibrahim J., Sondak V., Ernstoff M.S., Rao U. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004, 10:1670-1677.
104. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., Blum R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996, 14:7-17.
105. Mocellin S., Pasquali S., Rossi C.R., Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst 2010, 102:493-501.
106. Wheatley K., Ives N., Eggermont A., Kirkwood J., Cascinelli N., Markovic S.N., et al. Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol (Meeting Abstracts) 2007, 25:8526.
107. Wheatley K., Ives N., Hancock B., Gore M., Eggermont A., Suciu S. Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 2003, 29:241-252.
108. Eggermont A.M., Suciu S., Santinami M., Testori A., Kruit W.H., Marsden J., et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008, 372:117-126.
109. Eggermont A.M., Suciu S., Santinami M., Kruit W., Testori A., Marsden J., et al. EORTC 18991 phase III trial: long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: long-term results at 7.6-years follow-up. J Clin Oncol 2011, 29. [abstr 8506b].
110. Kirkwood J.M., Bender C., Agarwala S., Tarhini A., Shipe-Spotloe J., Smelko B., et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002, 20:3703-3718.
111. Yurkovetsky Z.R., Kirkwood J.M., Edington H.D., Marrangoni A.M., Velikokhatnaya L., Winans M.T., et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res 2007, 13:2422-2428.
112. Hillner B.E. Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma. Eur J Cancer 1998, 34(Suppl. 3):S18-21.
113. Hillner B.E., Kirkwood J.M., Atkins M.B., Johnson E.R., Smith T.J. Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997, 15:2351-2358.
114. Stewart S.L., King J.B., Thompson T.D., Friedman C., Wingo P.A. Cancer mortality surveillance-United States, 1990-2000. MMWR Surveill Summ 2004, 53:1-108.
115. Berry D.A., Cronin K.A., Plevritis S.K., Fryback D.G., Clarke L., Zelen M., et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005, 353:1784-1792.
116. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
117. Peto R., Davies C., Godwin J., Gray R., Pan H.C., Clarke M., et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012, 379:432-444.
118. Bria E., Nistico C., Cuppone F., Carlini P., Ciccarese M., Milella M., et al. Benefit of taxanes as adjuvant chemotherapy for early breast cancer: pooled analysis of 15,500 patients. Cancer 2006, 106:2337-2344.
119. Dowsett M., Cuzick J., Ingle J., Coates A., Forbes J., Bliss J., et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010, 28:509-518.
120. Viani G.A., Afonso S.L., Stefano E.J., De Fendi L.I., Soares F.V. Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: a meta-analyses of published randomized trials. BMC Cancer 2007, 7:153.
121. Berry D.A., Cirrincione C., Henderson I.C., Citron M.L., Budman D.R., Goldstein L.J., et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295:1658-1667.
122. Martín M., Pienkowski T., Mackey J., Pawlicki M., Guastalla J.P., Weaver C., et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005, 352:2302-2313.
123. Henderson I.C., Berry D.A., Demetri G.D., Cirrincione C.T., Goldstein L.J., Martino S., et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003, 21:976-983.
124. Mamounas E.P., Bryant J., Lembersky B., Fehrenbacher L., Sedlacek S.M., Fisher B., et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005, 23:3686-3696.
125. Roché H., Fumoleau P., Spielmann M., Canon J.L., Delozier T., Serin D., et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006, 24:5664-5671.
126. Martin M., Rodriguez-Lescure A., Ruiz A., Alba E., Calvo L., Ruiz-Borrego M., et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008, 100:805-814.
127. Jones S.E., Savin M.A., Holmes F.A., O'Shaughnessy J.A., Blum J.L., Vukelja S., et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006, 24:5381-5387.
128. Sparano J.A., Wang M., Martino S., Jones V., Perez E.A., Saphner T., et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358:1663-1671.
129. Citron M.L., Berry D.A., Cirrincione C., Hudis C., Winer E.P., Gradishar W.J., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003, 21:1431-1439.
130. Venturini M., Del Mastro L., Aitini E., Baldini E., Caroti C., Contu A., et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J Natl Cancer Inst 2005, 97:1724-1733.
131. Fisher B., Dignam J., Bryant J., DeCillis A., Wickerham D.L., Wolmark N., et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996, 88:1529-1542.
132. Tormey D.C., Gray R., Abeloff M.D., Roseman D.L., Gilchrist K.W., Barylak E.J., et al. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: an Eastern Cooperative Oncology Group trial. J Clin Oncol 1992, 10:1848-1856.
133. Peto R, Davies C, on behalf of the ATLAS Collaboration. ATLAS (Adjuvant Tamoxifen, Longer Against Shorter): international randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11,500 women - preliminary results. Abstract 48. In: 30th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas: December 13-16, 2007.
134. Gray R.G., Rea D.W., Handley K., Marshall A., Pritchard M.G., Perry P., et al. ATTom (adjuvant Tamoxifen-To offer more?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6934 women with estrogen receptor-positive (ER+) or ER untested breast cancer - preliminary results. J Clin Oncol (Meeting Abstracts) 2008, 26:513.
135. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359:2131-2139.
136. Thürlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757.
137. Coombes R.C., Hall E., Gibson L.J., Paridaens R., Jassem J., Delozier T., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350:1081-1092.
138. Coombes R.C., Kilburn L.S., Snowdon C.F., Paridaens R., Coleman R.E., Jones S.E., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369:559-570.
139. Jonat W., Gnant M., Boccardo F., Kaufmann M., Rubagotti A., Zuna I., et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006, 7:991-996.
140. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 2007, 25:2006-2011.
141. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802.
142. Goss P.E., Ingle J.N., Pater J.L., Martino S., Robert N.J., Muss H.B., et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008, 26:1948-1955.
143. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005, 97:1262-1271.
144. Burstein H.J., Prestrud A.A., Seidenfeld J., Anderson H., Buchholz T.A., Davidson N.E., et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010, 28:3784-3796.
145. Goss P.E., Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001, 19:881-894.
146. Ryan P.D., Goss P.E. Adjuvant hormonal therapy in peri- and postmenopausal breast cancer. Oncologist 2006, 11:718-731.
147. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
148. Marty M., Cognetti F., Maraninchi D., Snyder R., Mauriac L., Tubiana-Hulin M., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005, 23:4265-4274.
149. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
150. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., Alanko T., Kataja V., Asola R., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820.
151. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
152. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011, 365:1273-1283.
153. Douillard J.Y. Adjuvant chemotherapy for non-small-cell lung cancer: it does not always fade with time. J Clin Oncol 2010, 28:3-5.
154. Sargent D.J., Wieand H.S., Haller D.G., Gray R., Benedetti J.K., Buyse M., et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005, 23:8664-8670.
155. Sargent D.J., Patiyil S., Yothers G., Haller D.G., Gray R., Benedetti J., et al. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007, 25:4569-4574.
156. Sargent D., Sobrero A., Grothey A., O'Connell M.J., Buyse M., André T., et al. Evidence for cure by adjuvant therapy in colon cancer: Observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009, 27:872-877.
157. de Gramont A., Hubbard J., Shi Q., O'Connell M.J., Buyse M., Benedetti J., et al. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol 2010, 28:460-465.
158. Sargent D.J., Yothers G., Van Cutsem E., Cassidy J., Saltz L., Wolmark N., et al. Use of two-year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: New data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, NSAPB C-06 and C-07, and C89803. J Clin Oncol (Meeting Abstracts) 2009, 27:4011.
159. Kefford R.F. Adjuvant therapy of cutaneous melanoma: the interferon debate. Ann Oncol 2003, 14:358-365.
160. Potti A., Mukherjee S., Petersen R., Dressman H.K., Bild A., Koontz J., et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006, 355:570-580.
161. Ribic C.M., Sargent D.J., Moore M.J., Thibodeau S.N., French A.J., Goldberg R.M., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257.
162. Sargent D.J., Marsoni S., Monges G., Thibodeau S.N., Labianca R., Hamilton S.R., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010, 28:3219-3226.
163. Chibon F., Lagarde P., Salas S., Perot G., Brouste V., Tirode F., et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 2010, 16:781-787.
164. Rodrigo R.S., Nathalie A., Elodie T., Gonzalo G.A., Philippe T., Francoise D., et al. Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas. Eur J Cancer 2011, 47:1319-1327.
165. Eggermont A.M., Suciu S., Testori A., Kruit W.H., Marsden J., Punt C.J., et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012, 48:218-225.
166. Kerr D., Gray R., Quirke P., Watson D., Yothers G., Lavery I.C., et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol (Meeting Abstracts) 2009, 27:4000.
167. Rosen G., Caparros B., Huvos A.G., Kosloff C., Nirenberg A., Cacavio A., et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 1982, 49:1221-1230.
168. Schöffski P., Casali P.G., Taron M., Van Oosterom A.T., Judson I.R., Grosso F., et al. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). J Clin Oncol 2006, 24. [abstr 9522].
169. Eggermont A.M., Suciu S., Testori A., Kruit W.H., Marsden J., Punt C.J., et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012, 48:218-225.
170. Dowsett M., Cuzick J., Wale C., Forbes J., Mallon E.A., Salter J., et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. J Clin Oncol 2010, 28:1829-1834.
171. Albain K.S., Barlow W.E., Shak S., Hortobagyi G.N., Livingston R.B., Yeh I.T., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11:55-65.
172. Kim C., Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol 2010, 7:340-347.
173. Sparano J.A., Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008, 26:721-728.
174. Cardoso F., Van't Veer L., Rutgers E., Loi S., Mook S., Piccart-Gebhart M.J. Clinical application of the 70-gene profile: the MINDACT trial. J Clin Oncol 2008, 26:729-735.
175. Goetz M.P., Rae J.M., Suman V.J., Safgren S.L., Ames M.M., Visscher D.W., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005, 23:9312-9318.
176. Goetz M.P., Knox S.K., Suman V.J., Rae J.M., Safgren S.L., Ames M.M., et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007, 101:113-121.
177. Schroth W., Goetz M.P., Hamann U., Fasching P.A., Schmidt M., Winter S., et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009, 302:1429-1436.
178. Lash T.L., Lien E.A., Sørensen H.T., Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection?. Lancet Oncol 2009, 10:825-833.
179. Vansteenkiste J.F., Zielinski M., Dahabreh I.J., Linder A., Lehmann F., Gruselle O., et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts) 2008, 26:7501.
180. AJCC cancer staging manual 2010, Springer-Verlag, New York, NY. 7th Edn. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, A. Trotti (Eds.).
181. Bhangu A.A., Beard J.A., Grimer R.J. Should soft tissue sarcomas be treated at a specialist centre?. Sarcoma 2004, 8:1-6.
182. Strander H., Bauer H.C., Brosjo O., Fernberg J.O., Kreicbergs A., Nilsonne U., et al. Long-term adjuvant interferon treatment of human osteosarcoma. A pilot study. Acta Oncol 1995, 34:877-880.
183. Ribas A., Antonia S., Sosman J., Kirkwood J.M., Redman B., Gajewski T.F., et al. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma. J Clin Oncol (Meeting Abstracts) 2007, 25:3000.
184. Hamid O., Chin K., Li J., Neyns B., Linette G., Negrier S., et al. Dose effect of ipilimumab in patients with advanced melanoma: results from a phase II, randomized, dose-ranging study. J Clin Oncol (Meeting Abstracts) 2008, 26:9025.
185. + regulatory T cell function. Science 2008, 322:271-275.
186. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
187. Long G.V., Kefford R.F., Carr P.J.A., Brown M.P., Curtis M., Ma B., et al. Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (mut) BRAF kinase: evidence of activity. Ann Oncol 2010, 21(Suppl. 8):LBA27.
188. Infante J.R., Falchook G.S., Lawrence D.P., Weber J.S., Kefford R.F., Bendell J.C., et al. Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). J Clin Oncol 2011, 29(Suppl.). [abstr CRA8503].
189. Long G.V., Wilmott J.S., Howle J.R., Chatfield M.D., Tembe V., Thompson J.F., et al. Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi). J Clin Oncol 2011, 29. [abstr 8542].
190. Kruit W.H., Suciu S., Dreno B., Chiarion-Sileni V., Mortier L., Robert C., et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label phase II study of the EORTC Melanoma Group (16032-18031). J Clin Oncol (Meeting Abstracts) 2008, 26:9065.
191. Louahed J., Gruselle O., Gaulis S., Coche T., Eggermont A.M., Kruit W., et al. Expression of defined genes identified by pretreatment tumor profiling: association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032-18031). J Clin Oncol (Meeting Abstracts) 2008, 26:9045.
192. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008, 26:3552-3559.
193. Sargent D.J., Goldberg R.M., Jacobson S.D., Macdonald J.S., Labianca R., Haller D.G., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345:1091-1097.
194. McCowan C., Shearer J., Donnan P.T., Dewar J.A., Crilly M., Thompson A.M., et al. Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 2008, 99:1763-1768.